97 related articles for article (PubMed ID: 34164591)
1. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation.
Giri VN; Obeid E; Gross L; Bealin L; Hyatt C; Hegarty SE; Montgomery S; Forman A; Bingler R; Kelly WK; Dicker AP; Winheld S; Trabulsi EJ; Chen DYT; Lallas CD; Allen BA; Daly MB; Gomella LG
JCO Precis Oncol; 2017 May; 1():. PubMed ID: 34164591
[TBL] [Abstract][Full Text] [Related]
2. Multigene Panel Testing for Hereditary Cancer Risk.
Grissom AA; Friend PJ
J Adv Pract Oncol; 2016; 7(4):394-407. PubMed ID: 29225998
[No Abstract] [Full Text] [Related]
3. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.
Loeb S; Keith SW; Cheng HH; Leader AE; Gross L; Sanchez Nolasco T; Byrne N; Hartman R; Brown LH; Pieczonka CM; Gomella LG; Kelly WK; Lallas CD; Handley N; Mille PJ; Mark JR; Brown GA; Chopra S; McClellan A; Wise DR; Hollifield L; Giri VN
JCO Precis Oncol; 2024 Mar; 8():e2300552. PubMed ID: 38452310
[TBL] [Abstract][Full Text] [Related]
4. 2023 Canadian Urological Association guideline: Genetic testing in prostate cancer.
Rendon RA; Selvarajah S; Wyatt AW; Kolinsky M; Schrader KA; Fleshner NE; Kinnaird A; Merrimen J; Niazi T; Saad F; Shayegan B; Wood L; Chi KN; Black P; Sridhar S; Yip S
Can Urol Assoc J; 2023 Oct; 17(10):314-325. PubMed ID: 37851913
[No Abstract] [Full Text] [Related]
5. Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.
Rebhan K; Stelzer PD; Pradere B; Rajwa P; Kramer G; Hofmann B; Resch I; Yurdakul O; Laccone FA; Bujalkova MG; Smogavec M; Tan YY; Ristl R; Shariat SF; Egger G; Hassler MR
World J Urol; 2023 Aug; 41(8):2091-2097. PubMed ID: 37528288
[TBL] [Abstract][Full Text] [Related]
6. Recent Research Advances in Double-Strand Break and Mismatch Repair Defects in Prostate Cancer and Potential Clinical Applications.
Jaworski D; Brzoszczyk B; Szylberg Ł
Cells; 2023 May; 12(10):. PubMed ID: 37408208
[TBL] [Abstract][Full Text] [Related]
7. Delivering Genetic Testing for Patients with Prostate Cancer: Moving Beyond Provider Knowledge as a Barrier to Care.
Gunn CM; Li EX; Gignac GA; Pankowska M; Loo S; Zayhowski K; Wang C
Cancer Control; 2023; 30():10732748221143884. PubMed ID: 36946278
[TBL] [Abstract][Full Text] [Related]
8. DNA repair deficiency as circulating biomarker in prostate cancer.
Catalano M; Generali D; Gatti M; Riboli B; Paganini L; Nesi G; Roviello G
Front Oncol; 2023; 13():1115241. PubMed ID: 36793600
[TBL] [Abstract][Full Text] [Related]
9. Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study.
Vlaming M; Bleiker EMA; van Oort IM; Kiemeney LALM; Ausems MGEM
BMC Cancer; 2022 Dec; 22(1):1365. PubMed ID: 36581909
[TBL] [Abstract][Full Text] [Related]
10. Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families.
Leader AE; Mercado J; Klein A; Hyatt C; Gross L; Brandt R; Giri VN
J Community Genet; 2022 Dec; 13(6):547-556. PubMed ID: 35869324
[TBL] [Abstract][Full Text] [Related]
11. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
[TBL] [Abstract][Full Text] [Related]
12. Germline pathogenic variants in unselected Korean men with prostate cancer.
So MK; Ahn HK; Huh J; Kim KH
Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
[TBL] [Abstract][Full Text] [Related]
13. Implications of ACMG guidelines to identify high-risk acute lymphoblastic leukemia patients with hereditary cancer susceptibility syndromes (HCSS) in a highly consanguineous population.
Aslam S; Shabana ; Ahmed M
BMC Pediatr; 2021 Jun; 21(1):282. PubMed ID: 34134655
[TBL] [Abstract][Full Text] [Related]
14. Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer.
Saoud R; Heidar NA; Cimadamore A; Paner GP
Cells; 2020 Sep; 9(9):. PubMed ID: 32957584
[TBL] [Abstract][Full Text] [Related]
15. Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: a teachable moment for improved survivorship.
Bruneau M; Milliron BJ; Sinclair E; Obeid E; Gross L; Bealin L; Smaltz C; Butryn M; Giri VN
Support Care Cancer; 2021 Apr; 29(4):2145-2151. PubMed ID: 32876733
[TBL] [Abstract][Full Text] [Related]
16. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
Giri VN; Knudsen KE; Kelly WK; Cheng HH; Cooney KA; Cookson MS; Dahut W; Weissman S; Soule HR; Petrylak DP; Dicker AP; AlDubayan SH; Toland AE; Pritchard CC; Pettaway CA; Daly MB; Mohler JL; Parsons JK; Carroll PR; Pilarski R; Blanco A; Woodson A; Rahm A; Taplin ME; Polascik TJ; Helfand BT; Hyatt C; Morgans AK; Feng F; Mullane M; Powers J; Concepcion R; Lin DW; Wender R; Mark JR; Costello A; Burnett AL; Sartor O; Isaacs WB; Xu J; Weitzel J; Andriole GL; Beltran H; Briganti A; Byrne L; Calvaresi A; Chandrasekar T; Chen DYT; Den RB; Dobi A; Crawford ED; Eastham J; Eggener S; Freedman ML; Garnick M; Gomella PT; Handley N; Hurwitz MD; Izes J; Karnes RJ; Lallas C; Languino L; Loeb S; Lopez AM; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann M; Mille P; Miner MM; Morgan T; Moreno J; Mucci L; Myers RE; Nielsen SM; O'Neil B; Pinover W; Pinto P; Poage W; Raj GV; Rebbeck TR; Ryan C; Sandler H; Schiewer M; Scott EMD; Szymaniak B; Tester W; Trabulsi EJ; Vapiwala N; Yu EY; Zeigler-Johnson C; Gomella LG
J Clin Oncol; 2020 Aug; 38(24):2798-2811. PubMed ID: 32516092
[TBL] [Abstract][Full Text] [Related]
17. BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update.
Junejo NN; AlKhateeb SS
Saudi Med J; 2020 Jan; 41(1):9-17. PubMed ID: 31915789
[TBL] [Abstract][Full Text] [Related]
18. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Paller CJ; Antonarakis ES; Beer TM; Borno HT; Carlo MI; George DJ; Graff JN; Gupta S; Heath EI; Higano CS; McKay RR; Morgans AK; Patnaik A; Petrylak DP; Rettig MB; Ryan CJ; Taplin ME; Whang YE; Vinson J; Cheng HH; Giri VN;
Clin Genitourin Cancer; 2019 Aug; 17(4):275-282.e1. PubMed ID: 31171481
[TBL] [Abstract][Full Text] [Related]
19. Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet intervention.
Milliron BJ; Bruneau M; Obeid E; Gross L; Bealin L; Smaltz C; Giri VN
Prostate; 2019 May; 79(7):778-783. PubMed ID: 30905089
[TBL] [Abstract][Full Text] [Related]
20. Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data.
Khiabanian H; Hirshfield KM; Goldfinger M; Bird S; Stein M; Aisner J; Toppmeyer D; Wong S; Chan N; Dhar K; Gheeya J; Vig H; Hadigol M; Pavlick D; Ansari S; Ali S; Xia B; Rodriguez-Rodriguez L; Ganesan S
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30246169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
